Why ALA Supports Keeping the Name Lipedema

You may have heard recent discussions about changing the name Lipedema to Lipalgia Syndrome. But what does that mean, and why does it matter?

In September 2026, the International Lipoedema Association (ILA) announced its support for the name Lipalgia Syndrome, which places a greater emphasis on pain as a defining symptom of the condition.

The American Lipedema Association (ALA) does not support changing the name at this time.

Lipedema is a complex condition that involves more than pain alone. While research continues to improve our understanding of the disease, there are still important questions about its underlying causes.

The name lipedema is also becoming more widely recognized by healthcare professionals, researchers, and insurers. Changing it now could create confusion and complicate ongoing efforts to improve diagnosis, education, and access to care.

ALA believes any future name change should be guided by stronger scientific understanding and international agreement that includes patients, healthcare professionals, and researchers.

We believe the priority should be advancing research, improving awareness, and helping people living with lipedema get the care they deserve.

Read ALA’s Full Position Paper (PDF) below to learn more about why we support keeping the name lipedema.

FAQ’s about renaming Lipedema

General FAQs


What is being proposed?
Who is the ILA?
Why does the ALA disagree?
Does the ALA think lipedema is the same as lymphedema?
Could the name ever change?

Patients and Members FAQs

Does this change my diagnosis?
My therapist or doctor called it lipalgia syndrome. Are they wrong?
Will this affect my insurance coverage?
Should I change my treatment?
How can I help?

Clinicians and Therapists FAQs

What term should I use in documentation?
Some CLT training programs now teach the new name. Should I use it?
What is the evidence for a fluid component?
What are the limits of that evidence?
What does the LIPLEG trial tell us?

Media FAQs

Is this a dispute between patient groups?
Does the ALA stand alone in this view?
Why does a name matter so much?
What would the ALA like to see happen?

Insurers and Partners FAQs

Should coverage policies change their terminology?
Does the debate change the evidence for treatment?
How should partners refer to the condition?

Scroll to Top